Lili Gil Valletta, Founder and CEO, CulturIntel and CIEN+, CNN, Fox News and MSNBC Media Commentator, Hispanic Markets Expert and Business Strategist, based in New York, NY

Customers, markets, and businesses may never be the same, which is why today, more than ever, we need to reimagine how we make data-driven decisions to proactively respond and innovate as leaders.

Unprecedented times call for unprecedented methods to understand people and proactively prepare for a "new normal." That is why going beyond traditional surveys, panels, or focus groups, Culturintel is using big data and artificial intelligence to better understand how COVID-19 is impacting people's lives and mindsets, across genders, generations, and ethnicities.

On May 14th, the audience learned about what the Culturintel COVID-19 People Impact Meter reveals after analyzing over 100 million organic and unbiased digital discussions as people share their experiences in real-time, with nobody asking.

Jerry O’Brien, CEO, Radisens Diagnostics, Ltd., based in County Cork, Ireland

As a result of their life-giving altruism, blood donors have high prevalence of iron deficiency with adverse effects including pregnancy complications, cognitive impairment and other conditions. Assessing iron stores in the lab post-donation is too late - a sensitive point-of-care test is needed as a duty of care. Other applications include improving pediatric care and as an emerging early-warning tool for acute respiratory infections. On May 14th, we will learn more about Radisens’ approach to addressing this unmet need with implications on one of health’s largest supply lines: blood donation.

Meet Jerry by logging in to Cavendish IQ.

Peter B. Heifetz, PhD, President and CEO, OrPro Therapeutics, Inc., based in San Diego, Calif.

Inflammation and airway obstruction in severe respiratory disease are significant drivers of morbidity and mortality that are not addressed by vaccines or anti-virals. We are developing a treatment to prevent severe respiratory disease progression and hospitalization in response to infection with SARS-Cov-2 and other acute viral respiratory pathogens, including emerging agents that could be the next pandemic. Designed for easy delivery in an inhaled form, this treatment provides a novel approach to addressing unmet medical needs across a spectrum of respiratory conditions including acute viral lung injury, acute respiratory distress syndrome (ARDS) and chronic lung diseases such as cystic fibrosis, bronchiectasis and COPD.

Meet Peter and OrPro by logging in to Cavendish IQ.